ReviewExperimental cell research2009
Mechanisms of ErbB receptor negative regulation and relevance in cancer.
Review in Experimental cell research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Tensins in Cancer: Integration of Their Domain Functions, Context-Dependent Regulation and Biomarker Potential.Biology · 2025Review
- Review
- Endogenous thrombopoietin promotes non-small-cell lung carcinoma cell proliferation and migration by regulating EGFR signalling.Journal of cellular and molecular medicine · 2020Article
- Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas.BMC veterinary research · 2020Article
- Article
- Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation.Veterinary research communications · 2019Article
- The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.The Journal of biological chemistry · 2019Article
- Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma.Oncology letters · 2017Article
- The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.Science signaling · 2016Article
- Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.Cancer management and research · 2016Review
- Smad7 Modulates Epidermal Growth Factor Receptor Turnover through Sequestration of c-Cbl.Molecular and cellular biology · 2015Article
- Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling.PloS one · 2015Article
- Cell surface epidermal growth factor receptors increase Src and c-Cbl activity and receptor ubiquitylation.The Journal of biological chemistry · 2014Article
- Sidekick for Membrane Simulations: Automated Ensemble Molecular Dynamics Simulations of Transmembrane Helices.Journal of chemical theory and computation · 2014Article
- Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination.The Journal of biological chemistry · 2014Article
- microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.Cancer research · 2014Article
- BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.PloS one · 2014Article
- CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.Cancer research · 2013Article
- Transformation of polarized epithelial cells by apical mistrafficking of epiregulin.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.Molecular and cellular biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.